VARIANT CJD AN UPDATE DR. HESTER WARD National CJD Surveillance Centre Edinburgh, UK

Slides:



Advertisements
Similar presentations
Sources and effects of bias in investigating links between adverse health outcomes and environmental hazards Frank Dunstan University of Wales College.
Advertisements

FDA Workshop “Data and Data Needs to Advance Risk Assessment for Emerging Infectious Diseases for Blood and Blood Products” November 29, 2011, Gaithersburg.
Removal of Prions by Plasma Fractionation Processes
Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.
PRION DISEASES BLOOD INFECTIVITY ISSUES Richard Knight NCJDSU.
Hepatitis A Last updated August Hepatitis A virus Associated with poor hygiene and sanitation - primarily transmitted from person-to-person via.
GRACE CHEN18 TH OCTOBER, OCCUPATIONAL AND ENVIRONMENTAL RISK FACTORS FOR MOTOR NEURONE DISEASE IN NZ Case - Control Study.
Predicting an Epidemic A Quantitative Assessment of TSE Sampling Data to Predict Outbreak Magnitude Aspen Shackleford HONR299J.
Analysis to Inform Decisions: Evaluating BSE Joshua Cohen and George Gray Harvard Center for Risk Analysis Harvard School of Public Health.
CJD Overview Bob Will, National CJD Surveillance Unit, Edinburgh, UK Associazione Italiana Encefalopatie da Prion Milano 3 Ottobre 2009.
Insert name of presentation on Master Slide Epidemiology Toolkit for Outbreak Investigation Meirion Evans Communicable Disease Surveillance Centre.
Are humans susceptible?
Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.
Hepatitis B: Epidemiology
Modeling the SARS epidemic in Hong Kong Dr. Liu Hongjie, Prof. Wong Tze Wai Department of Community & Family Medicine The Chinese University of Hong Kong.
Mad Cow Disease. Effects of Mad Cow disease Mad cow disease, or bovine spongiform encephalopathy (BSE), is a fatal brain disorder that occurs in cattle.
Babesiosis 1 st Quarter 2011 DIDE Training Jonah Long, MPH 1.
Harvard Center for Risk Analysis Evaluation of the Potential for BSE in the United States Joshua T. Cohen Keith Duggar George M. Gray Silvia Kreindel Harvard.
Canadian and U.S. BSE Risk Steven Anderson, Ph.D, MPP Office of Biostatistics & Epidemiology Center for Biologics Evaluation & Research U.S. Food & Drug.
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
Prion Diseases Microbes and Society Fall What is a Prion? Prion- small proteinaceous infectious particles which resist inactivation by procedures.
PRION DISEASE & PENTOSAN POLYSULPHATE IN THE UK Richard Knight NCJDSU University of Edinburgh Scotland.
Lecture 8 Objective 20. Describe the elements of design of observational studies: case reports/series.
Transmissible Spongiform Encephalopathies Ryan Maddox, MPH Creutzfeldt-Jakob Disease Surveillance Unit Division of Viral and Rickettsial Diseases National.
Development of FDA Recommendations for deferral of donors based on risk of BSE exposure Alan E. Williams, Ph.D. Director, Division of Blood Applications.
Health registers as a ressource for research Preben Bo Mortensen Director, Professor, DrMedSc National Centre for Register-based Research Aarhus University.
The Pathological Protein, Chapters 8-9 Rhiannon Aguilar HONR299J March 27, 2014.
Prions: Proteins Gone Bad
FVIII PRODUCT USAGE IN CLINICAL SETTINGS TSEAC October 31, 2005 Mark Weinstein, Ph.D. Office of Blood Research and Review CBER, FDA.
Investigation of vCJD in Leicestershire Dr Philip Monk & Dr Gerry Bryant.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
BSE: World Situation and USDA Response FDA TSE Advisory Committee Silver Spring, MD October 14, 2004 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA,
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
 Foreign Sources of Infection To − Vi Nguyen. Foreign Infection  Preventable environmental source of infection  Remove infectious material, epidemic.
Is for Epi Epidemiology basics for non-epidemiologists.
Variant Creutzfeldt-Jakob Disease Impact on U.S. Military Service Members Lt. Col. David Lincoln Deputy Director Armed Services Blood Program Office Unclassified.
Variant CJD and Plasma Products Risk assessment methods, assumptions and public health actions in the UK Kate Soldan & Anna Molesworth February 2005 Communicable.
The History of Chronic Wasting Disease Dr. Trent Bollinger, CCWHC One World, One Health Symposium Sept. 29, 2004.
HEPATITIS A EISENMAN ARIE, M.D Department of Internal Medicine B Rambam Medical Center Haifa, Israel
Chronic diseases as tracer conditions in international benchmarking of health systems: the example of diabetes 1 European Centre on Health of Societies.
TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.
BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.
Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.
Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.
Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.
VCJD World situation and Updates RG Will National CJD Research and Surveillance Unit Edinburgh, UK TSEAC meeting 1 st August 2011.
Blood-borne vCJD risk: in UK and other European populations Sheila M. Bird MRC Biostatistics Unit, CAMBRIDGE.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
Deferral of Blood and Plasma Donors for History of Transfusion in BSE Countries of Europe Alan E. Williams, Ph.D. Director, Division of Blood Applications.
David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.
1 A Simulation Model to Quantify the Spread of BSE in the United States Joshua Cohen and George Gray Harvard Center for Risk Analysis Harvard School of.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
Creutzfeldt-Jakob Disease Atif Chohan & Alex Brown.
Ethics in Clinical Genetics and Genomics Key Knowledge Year 4 Medical Ethics and Law Thread Course, The Ethox Centre, University of Oxford.
Mesothelioma in the South West of England : Trends, geographical distribution and gender differences Dr Sean McPhail, Andy Pring, Dr Julia Verne (contact.
TB in Yorkshire and the Humber Dr Simon Padfield 14 th Sept 2007.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
Cholangiocarcinoma – What is it?
INVESTIGATION OF AN OUTBREAK Dr. Nadia Aziz C.A.B.C.M. Department of community medicine.
Outbreak Investigation
(Bovine spongiform encephalopathy)
Outbreak Investigations
Prion Infection in Antibody Deficient Patients
Bovine Spongiform Encephalopathy Variant Creutzfeldt-Jakob disease
Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility  Simon Cauchemez,
Frequently Asked Questions About BSE
Dengue Virus Infections Investigation Guideline
Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility  Simon Cauchemez,
Presentation transcript:

VARIANT CJD AN UPDATE DR. HESTER WARD National CJD Surveillance Centre Edinburgh, UK

UK frequency of CJD

Variant CJD UK 114 definite & probable cases 89 definite cases- confirmed neuropathologically 14 probable cases- died- no post mortem 1 probable case- died- awaiting post mortem 10 probable cases- alive FRANCE: 3 definite & 2 alive probable cases REPUBLIC OF IRELAND: 1 definite case

Variant CJD AGE Median age at onset :26 years (range years) Median age at death :28 years (range years) GENDER: 60 males : 54 females DURATION OF ILLNES Median: 13 months (range months) GENETICS: All tested = MM at codon 129 (n= 97)

Courtesy of Nick Andrews, PHLS Statistics Unit, London

Geographical distribution of places of residence at onset of symptoms of vCJD cases (n=93)

Variant CJD - GEOGRAPHY

Dietary & Nutritional Survey of British Adults adults aged 16 to 64 years weighed, 7 day dietary records Household Food consumption & Expenditure Report , 000 households One week records of all foods entering home for consumption

Scatterplot of cumulative, age-standardised vCJD incidence against weekly consumption of other meat and meat products (grams) by region (Household Food Consumption and Expenditure: 1988) of cumulative, age-standardised vCJD incidence against weekly consumption of other meat and meat products (grams) by region (dietary data from Household Food Consumption and Expenditure:1988)

GEOGRAPHICALLY ASSOCIATED CASES (GACs) of vCJD

Geographically associated cases Definition : 2 or more cases of probable or definite vCJD where preliminary investigations suggest there is an association between the cases because of: a) Geographical proximity of residence at some time, either now or in the past; b) Other link with the same geographic area, eg. attending the same school or work place or attending functions in the same area.

The Leicester cluster 5 cases of variant CJD lived in Leicestershire (population 870, 000) Cumulative incidence: UK 1.5/ millionLeicester 5.7/ million 4/5 from Charnwood (142, 000): 28.2 / million Kulldorff’s method- spatial scan statistic- Leicestershire- most likely cluster (p<0.004) No other significant clusters (Cousens et al. Lancet 2001; 357: )

The Leicester cluster 4/5 were reported to have bought meat from butchers who processed whole carcass beasts & split the heads to remove the brains for commercial purposes Hypothesis- cases bought meat from butchers that split heads Tested - control study- matched each case to 6 community controls OR 15 ( )

The Leicester cluster If true: minimal incubation- between years Does this explain other cases in UK & in other countries? BUT Bias Interview with butchers Brain- where did it go?- food chain…..

Variant CJD- RISK FACTORS TO DATE from case control study: No evidence of increased risk of CJD associated with diet, surgery or occupation (although, some differences in diet between cases & controls) BUT- rare disease, recall bias, surrogate witnesses, small numbers, control recruitment

Size of the vCJD epidemic- predictions 1997: Cousens et al. Nature; 385: (n=14 vCJD) , 000 Back calculation MM genotype 2000: Ghani et al. Nature; 406: (n= 55 vCJD) Scenario analysis (> 5 million combinations of parameters) MM genotype < 2 cases vCJD per infectious bovine

Size of the epidemic- predictions 2001: Huillard d’Aignaux et al. Science; 294: (n= 82) Clinical cases: hundreds - few thousands Infected individuals: hundreds - millions, but long mean incubation period & so die from competing causes Close to peak of epidemic Back calculation- calc. number infected based on assumptions of when infected & incubation pd Exposure cut off MM genotype ? not reassuring re. potential secondary spread

Size of the epidemic- predictions 2001: Valleron et al. Science 294: (n=97) Total number of cases: 205 (upper limit 403) Mean incubation pd: 16.7 yrs (12- 23) Peak: 2000/ 2001 Bimodal age distribution Age at diagnosis= age at infection + incubation time. Assuming age of infection parallels BSE epidemic- incubation pd calc using deconvolution technique. Exposure cut off: 1990 Exponential decrease in susceptibility >15 years of age

Size of the epidemic- predictions 2002: Ferguson et al. Nature 9 January 2002; DOI /nature 709 Predictions of future cases of vCJD based on BSE infection of British sheep Bovine BSE only: Upper 95% CIs: vCJD cases Bovine + ovine BSE: Upper 95% CIs: 150, 000 vCJD cases (BSE endemic in national flock) Past exposure to BSE in UK: majority from cattle On- going exposure to BSE: sheep greater than cattle- reduce risk up to 90%-  age at slaughter &  SRM controls Many assumptions: epidemiology based on scrapie & experimental BSE in sheep, tissue infectivity during incubation

Size of the epidemic- predictions Conclusions Much uncertainty, esp incubation period, risk from sheep Only based on MM genotypes (40% of population) ? not necessarily reassuring if considering secondary spread

Transfusion Medicine Epidemiology Review (TMER) Joint project between National Blood Service & NCJDSU AIM: to investigate whether any evidence that CJD, including vCJD, may be transmitted via blood supply

TMER- vCJD TMER All definite + probable cases vCJD- reported to transfusion service of relevant country (England, Wales, Scotland & Northern Ireland) If a donor- trace fate of all donations- recipient details passed to NCJDSU Reverse TMER vCJD cases (& matched controls) who have received blood transfusions- details passed to BTS Details of donors passed back to NCJDSU

TMER- vCJD RESULTS (April 2001) (n= 87 vCJD cases) TMER 8 cases vCJD were blood donors- 22 recipients between None have developed CJD to date- 9 have died from other causes None have registered as blood donors

TMER- vCJD Reverse TMER 4 cases of vCJD received blood components ( case 103 of these) 111 donors- none have developed CJD to date

National CJD Surveillance Unit, UK Director & Neuropathology- Professor J. Ironside Neurology- Professor R.G. Will & Dr. R. Knight Protein Biochemistry- Dr. M. Head Genetics- Mr. M. Bishop CSF Biochemistry- Dr. A. Green Epidemiology- Dr. H. Ward Care co-ordinator- Dr. B. Weller

Blood transmission studies: on going Tests of CJD Blood/ urine Screening vs. diagnostic

DIAGNOSTIC CRITERIA FOR vCJD IAProgressive neuropsychiatric disorder BDuration of illness > 6 months CRoutine investigations do not suggest an alternative diagnosis DNo history of potential iatrogenic exposure ENo evidence of a familial form of TSE IIAEarly psychiatric symptoms a BPersistent painful sensory symptoms b CAtaxia DMyoclonus or chorea or dystonia EDementia IIIAEEG does not show the typical appearance of sporadic CJD c (or no EEG performed) BBilateral pulvinar high signal on MRI scan IVAPositive tonsil biopsy d

DEFINITE:I A and neuropathological confirmation of vCJD (spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum) PROBABLE:I and 4/5 of II and III A and III B OR I and IV A d POSSIBLE:I and 4/5 of II and III A a depression, anxiety, apathy, withdrawal, delusions. b this includes both frank pain and/or dysaesthesia. c generalised triphasic periodic complexes at approximately one per second. d tonsil biopsy is not recommended routinely, nor in cases with EEG appearances typical of sporadic CJD, but may be useful in suspect cases in which the clinical features are compatible with vCJD and MRI does not show bilateral pulvinar high signal. e spongiform change and extensive PrP deposition with florid plaques, throughout the cerebrum and cerebellum.